Molecular Profiling in Glioblastoma: Prelude to Personalized Treatment

被引:16
|
作者
Mladkova, Nikol [1 ]
Chakravarti, Arnab [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Ctr Canc, Boston, MA 02114 USA
关键词
PHASE-II TRIAL; MALIGNANT GLIOMAS; IMATINIB MESYLATE; RECEPTOR; CLASSIFICATION; TEMOZOLOMIDE; RAPAMYCIN; SURVIVAL; THERAPY; UPDATE;
D O I
10.1007/s11912-009-0009-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor's molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [21] Non-animal glioblastoma models for personalized treatment
    Zottel, Alja
    Jovcevska, Ivana
    Samec, Neja
    HELIYON, 2023, 9 (10)
  • [22] Perspective: Cellular and Molecular Profiling Technologies in Personalized Oncology
    Cruz, Andrea
    Peng, Weng Kung
    JOURNAL OF PERSONALIZED MEDICINE, 2019, 9 (03):
  • [23] Molecular Profiling and Personalized Medicine From the Guest Editor
    Chu, Edward
    CANCER JOURNAL, 2011, 17 (02): : 69 - 70
  • [24] Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
    Lili, Loukia N.
    Matyunina, Lilya V.
    Walker, L. DeEtte
    Daneker, George W.
    McDonald, John F.
    PANCREAS, 2014, 43 (02) : 198 - 211
  • [25] Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach
    D'Alessandris, Quintino G.
    Martini, Maurizio
    Cenci, Tonia
    DI Bonaventura, Rina
    Lauretti, Liverana
    Stumpo, Vittorio
    Olivi, Alessandro
    Larocca, Luigi M.
    Pallini, Roberto
    Montano, Nicola
    JOURNAL OF NEUROSURGICAL SCIENCES, 2023, 67 (01) : 103 - 107
  • [26] Clinical use of personalized molecular biomarkers in patients with glioblastoma.
    Holdhoff, M.
    Blakeley, J. O.
    Carson, C.
    Ferrigno, C. H.
    Blair, L.
    Balmanoukian, A. S.
    Burger, P.
    Grossman, S. A.
    Diaz, L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Identification of molecular subtypes of glioblastoma by gene expression profiling
    Paul S Mischel
    Ruty Shai
    Tao Shi
    Steve Horvath
    Kan V Lu
    Gheeyoung Choe
    David Seligson
    Thomas J Kremen
    Aarno Palotie
    Linda M Liau
    Timothy F Cloughesy
    Stanley F Nelson
    Oncogene, 2003, 22 : 2361 - 2373
  • [28] Identification of molecular subtypes of glioblastoma by gene expression profiling
    Mischel, PS
    Shai, R
    Shi, T
    Horvath, S
    Lu, KV
    Choe, G
    Seligson, D
    Kremen, TJ
    Palotie, A
    Liau, LM
    Cloughesy, TF
    Nelson, SF
    ONCOGENE, 2003, 22 (15) : 2361 - 2373
  • [29] Impact of molecular profiling on clinical trial design for glioblastoma
    Chakravarti A.
    Tyndall E.
    Palanichamy K.
    Mehta M.
    Aldape K.
    Loeffler J.
    Current Oncology Reports, 2007, 9 (1) : 71 - 79
  • [30] MOLECULAR PROFILING PREDICTS EARLY AND LATE PROGRESSION IN GLIOBLASTOMA
    Nikolopoulos, Marina
    Wu, Megan
    Bahcheli, Alexander
    Kellett, Sorcha
    Myrehaug, Sten
    Sahgal, Arjun
    Spears, Melanie
    Pai, Shraddha
    Bayani, Jane
    Das, Sunit
    NEURO-ONCOLOGY, 2024, 26